News

The Duke Human Vaccine Institute plays an integral role in modernizing flu vaccines.

Duke is the only institution to receive a contract in each of the three CIVICs components, including work to design and evaluate influenza vaccine approaches, manufacture and evaluate the safety and toxicity of vaccine platforms, and conduct clinical trials for influenza vaccines.

School of Medicine Expands to RTP, January 2021

The Duke University School of Medicine is expanding into a newly-leased research center in the Research Triangle Park (RTP). The 273,000 square foot facility in the Parmer RTP research and development campus, formerly home to pharmaceutical maker GlaxoSmithKline, is currently being renovated to accommodate School of Medicine faculty, staff and labs as soon as January 2021.